Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Sarcoma 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 49fludarabine phosphate 37Peripheral Blood Stem Cell Transplantation 32Cyclosporine 30Mycophenolic Acid 29Busulfan 27Whole-Body Irradiation 25Radiotherapy 24Antilymphocyte Serum 24Filgrastim 23Melphalan 18Tacrolimus 16Methylprednisolone 15Cord Blood Stem Cell Transplantation 15Methotrexate 14Etoposide 12Thiotepa 8sargramostim 6Cytarabine 6Rituximab 5fludarabine 4aldesleukin 4Therapeutics 4Sirolimus 4Carmustine 4Biopsy 4thymoglobulin 3Polymerase Chain Reaction 3Paclitaxel 3Itraconazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × veltuzumab × Sarcoma × Clear all
NCT00546793 2021-08-16

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Gilead Sciences

Phase 1/2 Completed
32 enrolled
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, B-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡